Veracyte's stock surged 6.08% in pre-market trading on Thursday, following a bullish analyst update.
The move comes after Needham analyst Michael Matson maintained a Buy rating on the company and raised his price target to $48.00 from $44.00. The analyst cited accelerating growth, expanding margins, and pipeline-driven upside as key factors supporting the increased valuation.